Peptide therapy

As of April 2026, the Therapeutic Goods Administration (TGA) has raised concerns regarding the safety, quality, and regulation of many compounded peptide products, alongside stricter requirements for their prescribing, compounding, and advertising.

As a result, we have made the decision to pause peptide therapy services to ensure we remain fully compliant and aligned with current standards, until a clearer and safer regulatory framework is established.